Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06936943
Recruiting Phase 2

ONO-4538 Study in Patients With Richter's Transformation

NCT06936943 · tracked via the Priya Life Science Japan tracker
Sponsor
Ono Pharmaceutical Co., Ltd
Phase
Phase 2
Started
2025-11-19
Last updated
2026-02-13

Condition(s) studied

Richter's Transformation

Investigational drug(s) / intervention(s)

ONO-4538 →

ONO-4538: every 4 weeks

Study summary

Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histological diagnosis of diffuse large B-cell lymphoma (DLBCL)-type or Hodgkin lymphoma(HL)-type Richter's transformation with a history of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) * In the case of DLBCL-type Richter's transformation, refractory, intolerant or ineligible for treatment of DLBCL * Patients with measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Expected to survive for 90 days or more Exclusion Criteria: * Serious complications * Active multiple cancers * Active central nervous system (CNS) disease * History of allogeneic hematopoietic stem cell transplantation

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Aichi Cancer Center Nagoya Aichi-ken Recruiting
Kyusyu University Hospital Fukuoka Fukuoka Recruiting
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Hiroshima Recruiting
Hokkaido University Hospital Sapporo Hokkaido Recruiting
Kyoto University Hospital Kyoto Kyoto Recruiting
Tohoku University Hospital Sendai Miyagi Recruiting
Niigata University Medical & Dental Hospital Niigata Niigata Recruiting
Kindai University Hospital Ōsaka-sayama Osaka Recruiting
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Bunkyō-Ku Tokyo Recruiting
National Cancer Center Hospital Chuo Ku Tokyo Recruiting

More Ono Pharmaceutical Co., Ltd. trials in Japan

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia Recruiting
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus Recruiting
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors Active, not recruiting
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer Active, not recruiting
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06936943 on ClinicalTrials.gov ↗ ← All trials in Japan